Search scope:
排序： Display mode:
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
Frontiers of Medicine 2021, Volume 15, Issue 1, Pages 108-115 doi: 10.1007/s11684-019-0730-8
Keywords： post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation lymphoid malignancies
Frontiers of Medicine 2022, Volume 16, Issue 6, Pages 957-968 doi: 10.1007/s11684-021-0910-1
Keywords： skin and soft tissue infections hematopoietic stem cell transplantation risk stratification system mortality
Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang
Frontiers of Medicine 2015, Volume 9, Issue 3, Pages 304-311 doi: 10.1007/s11684-015-0400-4
Keywords： chronic myeloid leukemia imatinib dasatinib nilotinib allogeneic hematopoietic stem cell transplantation
Frontiers of Medicine 2021, Volume 15, Issue 5, Pages 728-739 doi: 10.1007/s11684-021-0833-x
Keywords： second hematopoietic stem cell transplantation acute leukemia relapse chemotherapy modified donor lymphocyte infusion
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
Frontiers of Medicine 2019, Volume 13, Issue 2, Pages 238-249 doi: 10.1007/s11684-017-0599-3
Keywords： interferon-α hematopoietic stem cell transplantation minimal residual disease donor lymphocyte infusion
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
Frontiers of Medicine 2019, Volume 13, Issue 3, Pages 354-364 doi: 10.1007/s11684-018-0665-5
Keywords： donor leukocyte infusion hematopoietic stem cell transplantation interferon-
Xiaodong Mo, Xiaojun Huang
Frontiers of Medicine 2013, Volume 7, Issue 3, Pages 306-315 doi: 10.1007/s11684-013-0279-x
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for
Keywords： partially matched related donor hematopoietic stem cell transplantation allogeneic
The Dual Regulatory Roles of Macrophages in Acute Allogeneic Organ Graft Rejection Review
Liang Tan, Yinan Guo, Chang Feng, Yangxiao Hou, Xubiao Xie, Yong Zhao
Engineering 2022, Volume 10, Issue 3, Pages 21-29 doi: 10.1016/j.eng.2021.10.015
Innate immune cells are critical for transplant response. As an important cellular component of innate immune cells, macrophages are the predominate infiltrated cells in allografts, and macrophage accumulation in allografts is negatively associated with the short- and long-term outcomes of organ transplantation. Macrophages are functionally heterogeneous and plastic. They participate in organ graft rejection through multiple pathways, including antigen presentation, the expression of costimulatory molecules and cytokines, and direct cytotoxicity and injury ability to allografts. However, some macrophage subpopulations, such as regulatory macrophages, can protect allografts from immune rejection and promote transplant immune tolerance with their immune regulatory properties. Although researchers recognize the potential roles macrophages play in allograft injury, they pay insufficient attention to the diverse roles of macrophages in allograft rejection. We herein briefly summarize the distinctive roles of macrophages in acute transplant immune response and the effect of immunosuppressive drugs on macrophages. Greater attention should be paid to the complex and critical function of macrophages in allograft rejection, and more effort should be put into developing immunosuppressive drugs that specifically target macrophages, which would ultimately improve the long-term survival of organ grafts in patients.
Keywords： Macrophages Transplantation Tolerance Rejection Regulatory macrophage
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
Engineering 2021, Volume 7, Issue 2, Pages 162-169 doi: 10.1016/j.eng.2020.12.005
We aimed to develop a disease risk comorbidity index (DRCI) based on disease risk index (DRI) and Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in patients receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We identified the prognostic factors of disease-free survival (DFS) in a training subset (n = 593), then assigned a weighted score using these factors to the remaining patients (validation subset; n = 296). The multivariable model identified two independent predictors of DFS: DRI and HCT-CI before transplantation. In this scoring system, we assigned a weighted score of 2 to very high-risk DRI, and assigned a weighted score of 1 to high-risk DRI and intermediate- and high-risk HCT-CI (i.e., haplo-DRCI). In the validation cohort, the three-year DFS rate was 65.2% (95% confidence interval (CI), 58.2%–72.2%), 55.8% (95% CI, 44.9%–66.7%), and 32.0% (95% CI, 5.8%–58.2%) for the low-, intermediate-, and high-risk group, respectively (P = 0.005). Haplo-DRCI can also predict DFS in disease-specific subgroups, particularly in acute leukemia patients. Increasing score was also significantly predictive of increased relapse, increased non-relapse mortality (NRM), decreased DFS, and decreased overall survival (OS) in an independent historical cohort (n = 526). These data confirmed that haplo-DRCI could effectively risk stratify haplo-HSCT recipients and provide a tool to better predict who will best benefit from haplo-HSCT.
Keywords： Disease risk index Disease risk comorbidity index Hematopoietic cell transplantation comorbidity index Hematopoietic stem cell transplantation Haploidentical
Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang
Engineering 2019, Volume 5, Issue 1, Pages 150-155 doi: 10.1016/j.eng.2018.12.006
Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem
Keywords： Donor-derived CD19-targeted T cell infusion Hematopoietic stem cell transplantation B cell acute lymphoblastic leukemia Minimal residual disease
Title Author Date Type Operation
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
Journal Article
Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell
Journal Article
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult
Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang
Journal Article
Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed
Journal Article
syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
Journal Article
Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang
Journal Article
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation
Xiaodong Mo, Xiaojun Huang
Journal Article
The Dual Regulatory Roles of Macrophages in Acute Allogeneic Organ Graft Rejection
Liang Tan, Yinan Guo, Chang Feng, Yangxiao Hou, Xubiao Xie, Yong Zhao
Journal Article
Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
Journal Article
京公网安备 11010502051620号
